secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bio Green Med Solution, Inc. (BGMS)
CIK:        0001130166
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001104659-23-117199
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cyclacel reports Q3 net loss of $6.1M; cash runway only through end of 2023
---------------------------------------------------------------------------

- Cash equivalents $5.9M at Sep 30, 2023, down from $18.3M at Dec 31, 2022.
- Net loss of $6.1M for Q3 2023 vs $5.1M in Q3 2022; R&D spend rose to $5.2M.
- Available cash funds planned programs only through end of 2023; discretionary cuts could extend into Q2 2024.
- Fadraciclib dose escalation near RP2D selection; plogosertib recruiting at dose level 5 with epigenetic mechanism under study.
- UK R&D tax credits reduced to $0.6M in Q3 2023 from $1.0M due to legislative changes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130166/000110465923117199/0001104659-23-117199-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130166/000110465923117199/tm2330442d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-117199

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer